Chip stocks fall with Nvidia after data center rev disappointment
Investing.com - Mizuho (NYSE:MFG) raised its price target on Hologic (NASDAQ:HOLX) to $75.00 from $70.00 on Thursday, while maintaining an Outperform rating on the medical technology company’s stock. According to InvestingPro data, Hologic maintains excellent financial health with a current ratio of 3.24, indicating strong liquidity. The company’s shares have declined nearly 10% year-to-date, despite showing robust operational metrics.
The price target increase follows Hologic’s fiscal third-quarter results, which exceeded expectations with an $18 million revenue beat and earnings per share $0.03 above consensus estimates. The company’s Skeletal Health segment posted $31 million in revenue versus $23 million expected, while the Interventional Breast segment delivered $100 million compared to Street expectations of $83 million. With a P/E ratio of 27.02 and strong gross profit margins of 61%, InvestingPro analysis suggests the stock is currently trading close to its Fair Value.
Hologic raised the lower end of its full-year revenue guidance to a range of $4.081-$4.091 billion, up from its previous forecast of $4.05-$4.10 billion. The company cited improved performance in its Breast Health segment and continued momentum from its Endomag acquisition as factors behind the revised outlook.
The medical device maker also increased its adjusted earnings per share guidance by $0.04 at the midpoint, reflecting an estimated $0.07 benefit from lower tariffs. This positive impact is partially offset by headwinds in the company’s Cytology business, ongoing USAID funding impacts, and adverse product mix shifts.
Mizuho noted that Hologic’s portfolio turnaround is still expected to lag into early next year, which may keep the stock trading within a range as speculation about potential deals continues to circulate in the market. For deeper insights into Hologic’s financial health and growth prospects, InvestingPro subscribers can access comprehensive analysis, including additional ProTips and detailed valuation metrics in the Pro Research Report, part of the platform’s coverage of over 1,400 US stocks.
In other recent news, Hologic Inc . reported its third-quarter 2025 earnings, surpassing Wall Street expectations. The company achieved an earnings per share (EPS) of $1.08, exceeding the forecast of $1.05. Hologic’s revenue for the quarter reached $1.024 billion, slightly above the anticipated $1.01 billion. These earnings and revenue results highlight a positive performance for the company. Despite the earnings beat, the stock experienced a dip in aftermarket trading, indicating investor caution amid broader economic concerns. Such fluctuations in stock price often reflect market sentiment rather than company performance. Analysts had projected these earnings and revenue figures, which the company managed to exceed. These developments are part of the recent updates concerning Hologic.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.